Work

Il primo paziente italiano affetto da linfoma diffuso a grandi cellule B trattato con axi-cel in seconda linea: innovazione e tradizione

Year: 2025

Type: article

Abstract: CAR-T cell therapy has revolutionized the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) within 12 months, replacing the use of high-dose chemotherapy with autologous stem cell reinfusion. Primary chemoresistance remains one of the most unfavorable prognostic scenarios for patients with DLBCL, despite the progress made with the introduction of anti-CD20 monoclonal antibodies in first-line treatment. Early identification of prognostic factors associated with clinical presentation represents an integrated approach that ensures rapid access to autologous anti-CD19 CAR-T therapy in selected cases that may benefit from treatment according to current standard indications.

Source: Recenti Progressi in Medicina

DOI: 10.1701/4450.44450

Authors: Stefania Bramanti, Davide Chizzoniti, Daniele Mannina

Institution: Fondazione Humanitas per la Ricerca

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Gilead Sciences